Compound management may seem straightforward but in reality, as the number of new compounds increases dramatically year-on-year, the management of large collections has become increasingly challenging.
The links between mitochondrial dysfunction and various diseases and pathological conditions are being increasingly revealed, such that mitochondrial analyses have gained renewed interest from both the academic research and drug discovery labs.
Despite an investment of billions of US dollars in the search of novel therapies, cancer still remains the leading cause of death in the world. This emphasises the need to identify novel tumour dependencies and molecular targets.
The recent high-profile translational failures in mouse models have highlighted the need for more relevant animal models. Advances in gene editing tools, including the CRISPR/Cas9 system, have enabled the modification of highly translational organisms such as rats and rabbits, and have also greatly reduced model development timelines.
By Dr Scott R. Burger, Louis Juliano, and Dr Wenshi Wang
For more than two decades, the biotechnology and pharmaceutical industries have been working to unlock the great potential of cell therapy, which uses products composed of living, functional cells to mediate the therapeutic effect.
Although the widespread use of target-focused libraries has led to the rapid expansion of novel chemistry as research tools in drug discovery to exploit many classes of drug target, the ubiquitin system still remains a largely untapped medicinal chemistry opportunity.
Biobanks or biorepositories are facilities that collect, process, store and distribute biospecimens and associated data, mainly for biological and medical research. They constitute a crucial resource, supporting cutting-edge investigation in fields such as oncology, genomics and personalised medicine, and the development of diagnostics and therapeutics.
By Dr Alexandre Akoulitchev, Dr Howard Womersley and Dr Phil Jordan
Interest in personalised medicine continues to grow, and epigenetic biomarkers are very informative in this respect, giving a clear indication of whether â and how â a patientâs gene expression profile has changed, as well as the rate of disease progression.